Deparment of Molecular Medicine, University of Pavia, via Forlanini 14, 27100, Pavia, Italy.
Neuroimaging Lab, Scientific Institute IRCCS Eugenio Medea, Bosisio Parini, Lecco, Italy.
Cerebellum. 2022 Dec;21(6):1144-1150. doi: 10.1007/s12311-021-01350-8. Epub 2021 Nov 30.
Joubert syndrome (JS) is a recessively inherited ciliopathy, characterized by a specific cerebellar and brainstem malformation recognizable on brain imaging as the "molar tooth sign" (MTS). Clinical signs include hypotonia, developmental delay, breathing abnormalities, and ocular motor apraxia. Older patients develop ataxia, intellectual impairment, and variable organ involvement. JS is genetically heterogeneous, with over 40 ciliary genes overall accounting for 65-75% cases. Thus, in recent years, the genetic diagnosis of JS has been based on the analysis of next-generation sequencing targeted gene panels. Since clinical features are unspecific and undistinguishable from other neurodevelopmental syndromes, the recognition of the MTS is crucial to address the patient to the appropriate genetic testing. However, the MTS is not always properly diagnosed, resulting either in false negative diagnoses (patients with the MTS not addressed to JS genetic testing) or in false positive diagnoses (patients with a different brain malformation wrongly addressed to JS genetic testing). Here, we present six cases referred for JS genetic testing based on inappropriate recognition of MTS. While the analysis of JS-related genes was negative, whole-exome sequencing (WES) disclosed pathogenic variants in other genes causative of distinct brain malformative conditions with partial clinical and neuroradiological overlap with JS. Reassessment of brain MRIs from five patients by a panel of expert pediatric neuroradiologists blinded to the genetic diagnosis excluded the MTS in all cases but one, which raised conflicting interpretations. This study highlights that the diagnostic yield of NGS-based targeted panels is strictly related to the accuracy of the diagnostic referral based on clinical and imaging assessment and that WES has an advantage over targeted panel analysis when the diagnostic suspicion is not straightforward.
杰伯综合征(JS)是一种常染色体隐性遗传的纤毛病,其特征是在脑影像学上可识别出特定的小脑和脑干畸形,即“磨牙征”(MTS)。临床症状包括肌张力低下、发育迟缓、呼吸异常和眼球运动失调。年长患者则出现共济失调、智力障碍和各种器官受累。JS 具有遗传异质性,总体上有超过 40 个纤毛基因,占 65-75%的病例。因此,近年来,JS 的基因诊断主要基于下一代测序靶向基因panel 的分析。由于临床特征不特异,与其他神经发育综合征难以区分,因此识别 MTS 对于将患者转介至适当的基因检测至关重要。然而,MTS 并不总是能得到正确诊断,导致假阴性诊断(有 MTS 但未进行 JS 基因检测的患者)或假阳性诊断(有不同的脑部畸形但被错误地转介至 JS 基因检测的患者)。在此,我们报告了 6 例因 MTS 识别不当而被转介至 JS 基因检测的病例。尽管对 JS 相关基因的分析结果为阴性,但全外显子组测序(WES)揭示了其他基因的致病性变异,这些基因导致了具有部分临床和神经影像学重叠的不同脑部畸形疾病。由一组对基因诊断不知情的小儿神经放射科专家对 5 例患者的脑部 MRI 进行重新评估,排除了所有病例的 MTS,但有 1 例存在争议。这项研究强调,基于下一代测序的靶向 panel 的诊断率与基于临床和影像学评估的诊断转诊的准确性密切相关,当诊断线索不明确时,WES 比靶向 panel 分析具有优势。